Santen Pharmaceutical Co Stock Profit Margin
| SNPHF Stock | USD 10.53 0.62 5.56% |
Santen Pharmaceutical Co fundamentals help investors to digest information that contributes to Santen Pharmaceutical's financial success or failures. It also enables traders to predict the movement of Santen Pink Sheet. The fundamental analysis module provides a way to measure Santen Pharmaceutical's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Santen Pharmaceutical pink sheet.
Santen |
Santen Pharmaceutical Co Company Profit Margin Analysis
Santen Pharmaceutical's Profit Margin measures overall efficiency of a company and shows its ability to withstand competition as well as defend against adverse conditions such as rising costs, falling prices, decline in sales or management distress. Profit margin tells investors how well the company executes on its overall pricing strategies as well as how effective the company in controlling its costs.
Current Santen Pharmaceutical Profit Margin | (0.03) % |
Most of Santen Pharmaceutical's fundamental indicators, such as Profit Margin, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Santen Pharmaceutical Co is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Profit Margin indicator shows the amount of money the company makes from total sales or revenue. It can provide a good insight into companies in the same sector, as well as help to identify trends of a company from year to year.
| Competition |
Based on the latest financial disclosure, Santen Pharmaceutical Co has a Profit Margin of -0.0303%. This is 99.73% lower than that of the Healthcare sector and significantly lower than that of the Drug Manufacturers—General industry. The profit margin for all United States stocks is 97.61% lower than that of the firm.
Santen Profit Margin Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Santen Pharmaceutical's direct or indirect competition against its Profit Margin to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Santen Pharmaceutical could also be used in its relative valuation, which is a method of valuing Santen Pharmaceutical by comparing valuation metrics of similar companies.Santen Pharmaceutical is currently under evaluation in profit margin category among its peers.
Santen Fundamentals
| Return On Equity | -0.0264 | |||
| Return On Asset | -0.001 | |||
| Profit Margin | (0.03) % | |||
| Operating Margin | (0) % | |||
| Current Valuation | 2.6 B | |||
| Shares Outstanding | 388.22 M | |||
| Shares Owned By Insiders | 3.21 % | |||
| Shares Owned By Institutions | 53.50 % | |||
| Price To Earning | 14.54 X | |||
| Price To Book | 1.39 X | |||
| Price To Sales | 0.01 X | |||
| Revenue | 266.26 B | |||
| Gross Profit | 156.59 B | |||
| EBITDA | 53.91 B | |||
| Net Income | 27.22 B | |||
| Cash And Equivalents | 69.53 B | |||
| Cash Per Share | 176.84 X | |||
| Total Debt | 32.93 B | |||
| Debt To Equity | 0.1 % | |||
| Current Ratio | 2.48 X | |||
| Book Value Per Share | 780.63 X | |||
| Cash Flow From Operations | 46.04 B | |||
| Earnings Per Share | 0.50 X | |||
| Price To Earnings To Growth | 20,399 X | |||
| Number Of Employees | 4.32 K | |||
| Beta | 0.38 | |||
| Market Capitalization | 2.95 B | |||
| Total Asset | 459.98 B | |||
| Retained Earnings | 230.22 B | |||
| Working Capital | 106.3 B | |||
| Current Asset | 156.63 B | |||
| Current Liabilities | 50.32 B | |||
| Annual Yield | 0.03 % | |||
| Five Year Return | 1.57 % | |||
| Net Asset | 459.98 B | |||
| Last Dividend Paid | 16.0 |
About Santen Pharmaceutical Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Santen Pharmaceutical Co's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Santen Pharmaceutical using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Santen Pharmaceutical Co based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Santen Pink Sheet
Santen Pharmaceutical financial ratios help investors to determine whether Santen Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Santen with respect to the benefits of owning Santen Pharmaceutical security.